Evaluation of immunohistochemistry using two different antibodies and procedures for primary lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangement

Oncology Letters

Volumn 8, Issue 5, 2014, Pages 2155-2159

  Akiba, Jun ^a   Kawahara, Akihiko ^b   Abe, Hideyuki ^b   Azuma, Koichi ^a   Yamaguchi, Tomohiko ^b   Taira, Tomoki ^b   Fukumitsu, Chihiro ^b   Takase, Yorihiko ^b   Yasumoto, Makiko ^a   Umeno, Yumi ^a   Todoroki, Keita ^a   Kurita, Takashi ^a   Yamaguchi, Rin ^a   Kage, Masayoshi ^b   Yano, Hirohisa ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY HOSPITAL   (Japan)

Author keywords

Adenocarcinoma; Anaplastic lymphoma kinase; Fluorescence in situ hybridization; Immunohistochemistry; Lung cancer

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CLONE 5A4 ANTIBODY; D5F3 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PRIMARY TUMOR;

EID: 84907149944     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2511     Document Type: Article

References (31)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Travis WD, Brambilla E, Noguchi M, et al: International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6: 244-285, 2011.
3. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21: 2237-2246, 2003.
4. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311, 2004.
5. Azzoli CG, Baker S Jr, Temin S, et al; American Society of Clinical Oncology: American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27: 6251-6266, 2009.
6. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004.
7. Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561-566, 2007.
8. Rodig SJ, Mino-Kenudson M, Dacic S, et al: Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 15: 5216-5223, 2009.
9. Shaw AT, Yeap BY, Mino-Kenudson M, et al: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27: 4247-4253, 2009.
10. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693-1703, 2010.
11. Takahashi T, Sonobe M, Kobayashi M, et al: Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 17: 889-897, 2010.
12. Yoshida A, Tsuta K, Nakamura H, et al: Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol 35: 1226-1234, 2011.
13. Wong DW, Leung EL, So KK, et al; University of Hong Kong Lung Cancer Study Group: The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 115: 1723-1733, 2009.
14. Christensen JG, Zou HY, Arango ME, et al: Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 6: 3314-3322, 2007.
15. Takeuchi K, Choi YL, Togashi Y, et al: KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 15: 3143-3149, 2009.
16. Yi ES, Boland JM, Maleszewski JJ, et al: Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol 6: 459-465, 2011.
17. FDA: FDA summary of safety and effectiveness data. http://www.accessdata.fda.gov/cdrh_docs/pdf11/p110012b.pdf. Accessed August 26, 2011.
18. Baselga E, Torrelo A, Drolet BA, Zambrano A, Alomar A and Esterly NB: Familial nonmembranous aplasia cutis of the scalp. Pediatr Dermatol 22: 213-217, 2005.
19. Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ and Weeks JC: HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 22: 854-863, 2004.
20. Gouvêa AP, Milanezi F, Olson SJ, Leitao D, Schmitt FC and Gobbi H: Selecting antibodies to detect HER2 overexpression by immunohistochemistry in invasive mammary carcinomas. Appl Immunohistochem Mol Morphol 14: 103-108, 2006.
21. Roche PC, Suman VJ, Jenkins RB, et al: Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 94: 855-857, 2002.
22. Vance GH, Barry TS, Bloom KJ, et al; College of American Pathologists: Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med 133: 611-612, 2009.
23. Allred DC and Swanson PE: Testing for erbB-2 by immunohistochemistry in breast cancer. Am J Clin Pathol 113: 171-175, 2000.
24. Conklin CM, Craddock KJ, Have C, Laskin J, Couture C and Ionescu DN: Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol 8: 45-51, 2013.
25. Mino-Kenudson M, Chirieac LR, Law K, et al: A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 16: 1561-1571, 2010.
26. Park HS, Lee JK, Kim DW, et al: Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer 77: 288-292, 2012.
27. Li Y, Pan Y, Wang R, et al: ALK-rearranged lung cancer in Chinese: a comprehensive assessment of clinicopathology, IHC, FISH and RT-PCR. PLoS One 8: e69016, 2013.
28. Kawahara A, Akiba J, Abe H, et al: Eml4-alk-positive lung adenocarcinoma with signet-ring cells. Diagn Cytopathol 42: 460-463, 2014.
29. Takamochi K, Takeuchi K, Hayashi T, Oh S and Suzuki K: A rational diagnostic algorithm for the identification of ALK rearrangement in lung cancer: a comprehensive study of surgically treated Japanese patients. PLoS One 8: e69794, 2013.
30. Selinger CI, Rogers TM, Russell PA, et al: Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 26: 1545-1553, 2013.
31. Lindeman NI, Cagle PT, Beasley MB, et al: Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med 137: 828-860, 2013.